These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1979744)

  • 1. Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. The Australian Zidovudine Study Group.
    Swanson CE; Cooper DA
    AIDS; 1990 Aug; 4(8):749-57. PubMed ID: 1979744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group.
    Swanson CE; Tindall B; Cooper DA
    AIDS; 1994 May; 8(5):625-34. PubMed ID: 8060543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
    Cooper DA; Pehrson PO; Pedersen C; Moroni M; Oksenhendler E; Rozenbaum W; Clumeck N; Faber V; Stille W; Hirschel B
    AIDS; 1993 Feb; 7(2):197-207. PubMed ID: 8096703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
    AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
    Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.
    Lancet; 1994 Apr; 343(8902):871-81. PubMed ID: 7908356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group.
    BMJ; 1992 Jan; 304(6818):13-7. PubMed ID: 1346505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
    Skowron G; Bozzette SA; Lim L; Pettinelli CB; Schaumburg HH; Arezzo J; Fischl MA; Powderly WG; Gocke DJ; Richman DD; Pottage JC; Antoniskis D; McKinley GF; Hyslop NE; Ray G; Simon G; Reed N; LoFaro ML; Uttamchandani RB; Gelb LD; Sperber SJ; Murphy RL; Leedom JM; Grieco MH; Zachary J; Hirsch MS; Spector SA; Bigley J; Soo W; Merigan TC
    Ann Intern Med; 1993 Mar; 118(5):321-30. PubMed ID: 8094279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
    Krown SE; Gold JW; Niedzwiecki D; Bundow D; Flomenberg N; Gansbacher B; Brew BJ
    Ann Intern Med; 1990 Jun; 112(11):812-21. PubMed ID: 1971504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
    Fischl MA; Parker CB; Pettinelli C; Wulfsohn M; Hirsch MS; Collier AC; Antoniskis D; Ho M; Richman DD; Fuchs E
    N Engl J Med; 1990 Oct; 323(15):1009-14. PubMed ID: 1977079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group.
    McKinney RE; Pizzo PA; Scott GB; Parks WP; Maha MA; Lehrman SN; Riggs M; Eddy J; Lane BA; Eppes SC
    J Pediatr; 1990 Apr; 116(4):640-7. PubMed ID: 2181102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time.
    Graham NM; Piantadosi S; Park LP; Phair JP; Rinaldo CR; Fahey JL
    J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1258-66. PubMed ID: 7901384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential survival of patients with AIDS according to the 1987 and 1993 CDC case definitions.
    Vella S; Chiesi A; Volpi A; Giuliano M; Floridia M; Dally LG; Binkin N
    JAMA; 1994 Apr; 271(15):1197-9. PubMed ID: 7908705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
    McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
    N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study.
    Stein DS; Graham NM; Park LP; Hoover DR; Phair JP; Detels R; Ho M; Saah AJ
    Ann Intern Med; 1994 Jul; 121(2):100-8. PubMed ID: 8017721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group.
    Koch MA; Volberding PA; Lagakos SW; Booth DK; Pettinelli C; Myers MW
    Arch Intern Med; 1992 Nov; 152(11):2286-92. PubMed ID: 1359846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.
    Mannucci PM; Gringeri A; Savidge G; Gatenby P; Laurian Y; Pabinger-Fasching I; Martinez-Vazquez JM; Hessey EW; Steel HM
    Br J Haematol; 1994 Jan; 86(1):174-9. PubMed ID: 7912097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.